Error loading player: No playable sources found
36751
Session II - Managing the Complexity of the CGTP Supply Chain
Date
June 6, 2022
This product is not available for individual purchase, but it is available as part of the following products:
The Cell and Gene Therapy Products (CGTP) Symposium: Manufacturing, Quality and Regulatory Considerations enables the exchange of scientific ideas and dialogue with regulators that form the basis of evolving regulatory practices in the development of these diverse and innovative products…
Cell, gene, and other novel therapies require carefully designed and well executed logistics solutions for supplying lifesaving medicine to patients. Biological material sourced and produced for autologous and allogeneic therapies must be strictly controlled for temperature, timeline, as well as chain of identity and custody. This complexity was expanded by the COVID pandemic which has caused disruption in supply of materials, as well as manufacturing and logistics processes. On the other hand, smart technologies, digital solutions, and innovative operation models have driven the rapid evolution of global CGT clinical and commercial distribution. This session will explore the following topics:
• Planning and ensuring manufacturing capacity to serve the patient/market need.
• Solving supply chain challenges for clinical and/or commercial cell therapy products.
• Case studies of digital solution (electronic system integration), smart technologies and operation model successfully applied in supply chain management.
• Planning and ensuring manufacturing capacity to serve the patient/market need.
• Solving supply chain challenges for clinical and/or commercial cell therapy products.
• Case studies of digital solution (electronic system integration), smart technologies and operation model successfully applied in supply chain management.
Session Chairs
Related Products
Session VI - Cell Therapies
The Cell Therapies products space is continuing to build on the potential for innovative treatments for unmet patient needs. Topics include cell products with unique manufacturing process, complex sourcing starting material, and assays with direct relevance to CQAs…
Identity testing by NGS as a means of risk mitigation
Imagine that you just completed a manufacturing run for a mission critical gene therapy vector. All of your release testing is underway, and you are days away from releasing your product. Per regulatory guidelines, identity testing is performed to confirm the vector sequence is as expected…
Accelerate Your Viral Vector Analytics with Automated Tools from Bio-Techne
Modern medicines call for modern technologies. Revolutionary cell and gene therapies offer significant promise to treat life-threatening diseases. Getting therapies to market quickly and efficiently requires accurate testing of critical quality attributes, including accurate viral vector analysis…
Session IV - Emerging Technologies
In recent years, cell and gene therapies have evolved rapidly into approved products for the treatment of both incurable genetic diseases as well as for the treatment of certain cancers…
